Ozempic to send foodmakers looking for healthier offerings
Companies selling unhealthy foods need to tweak their business models to counter the growing popularity of weight-loss drugs — or risk alienating investors, shows latest Bloomberg Markets survey.
By Lisa Pham, Naomi Kresge and Agnieszka de Sousa, Bloomberg
Nearly three out of four respondents said companies making or marketing sugary, fatty or ultra-processed foods should revise their game plans, either by shrinking portions, adjusting recipes or offloading assets altogether. Just over a quarter of the 303 respondents think Big Food can wait out the emerging threat from appetite-suppressing drugs like Zepbound, Ozempic and Wegovy.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
